Title: Bispecific ADC and Nanobody–Drug Conjugate Development Powered by the Fully Human RenMice Platform
Description:
Bispecific antibody–drug conjugates (ADCs) represent the next evolution of targeted cancer therapeutics and are rapidly emerging as a high-value modality across both solid tumors and hematological malignancies. By enabling dual-antigen engagement, bispecific ADCs can enhance tumor selectivity, reduce off-target toxicity and non-specific accumulation in healthy tissues, and potentially expand the therapeutic window while decreasing systemic adverse effects. While the outlook is promising, bispecific ADCs still encounter challenges, including complex manufacturing processes and the risk of heavy- and light-chain mispairing.
Nanobody–drug conjugates are a novel type of targeted anticancer therapy formed by conjugating nanobodies with cytotoxic drugs. Leveraging the small size, high stability, and superior tissue penetration of nanobodies, these conjugates offer more precise tumor targeting and efficient payload delivery, thereby enhancing therapeutic efficacy, particularly in solid tumor indications.
In this webinar, we will review the current ADC development landscape, discuss strategic considerations for target selection and drug screening, and showcase novel common light-chain bispecific ADCs and nanobody–drug conjugates enabled by the fully human RenMice antibody discovery platform.
Speaker:
Yanan Guo, Ph.D.
Executive Director of the Institute for Biologics
Biocytogen
